Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2012, with the report dated January 16, 2012. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility (PDMR), or connected persons under the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a regulatory disclosure regarding share acquisitions by specific individuals and does not contain consolidated financial statements.
Material Changes
The filing details an increase in notional interests in Ordinary shares and American Depositary Receipts (ADRs) for listed PDMRs. These increases resulted from the reinvestment of dividends paid to shareholders on July 7, 2011, and October 6, 2011. This notification supplements previous announcements made on October 7, 2011, and July 11, 2011.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that notional dividends accrued will be paid out proportionally based on the percentage of deferred annual bonus holdings that vest after the relevant three-year measurement period.
Important Facts for Investors
- Transaction Type: Acquisitions of Ordinary shares and ADRs via dividend reinvestment under a deferred bonus plan.
- Key Participants: Sir Andrew Witty, Mr. S M Bicknell, Mr. D S Redfern, Ms. C Thomas, Dr. P J T Vallance, Mrs. D P Connelly, Dr. M M Slaoui, and Mr. D E Troy.
- Share Prices: Ordinary shares were acquired at 1359.50 pence (July 7, 2011) and 1345 pence (October 6, 2011). ADRs were acquired at $43.59 (July 7, 2011) and $41.83 (October 6, 2011).
- Regulatory Basis: The transaction was notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).